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Summary Amyloidosis is an abnormal extracellular deposit, which can occur in several tissues.
The mechanism is not clearly deﬁned. In systemic amyloidosis, all the organs can be inﬁltrated,
but amyloid goiter as the initial manifestation of systemic amyloidosis is an exceedingly rare
condition. We report a rare case of a patient who presented an amyloid goiter as the ﬁrst man-
ifestation of systemic amyloidosis. This patient had a known Crohn’s disease. He developed a
goiter without compressive complications. Histologic examination revealed a diffuse amyloid
deposition surrounding thyroid follicles. The gland was enlarged with an eosinophilic and amor-
phic deposit. Conﬁrmation of amyloid was made by the presence of congophilia and apple-green
birefringence under polarized-light microscopy. An immunoreactivity was seen with AA protein.
Amyloid goiter is a rare manifestation of amyloidosis. About 250 cases of amyloid goiter have
been reported in the literature. The goiter enlarges rapidly and progressively, often becoming
compressive like thyroid cancer. The prognosis depends on the treatment of the amyloidosis
and the underlying chronic disease.
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myloid-associated (AA) or inﬂammatory amyloidosis is one
f the main forms of systemic amyloidosis, along with
mmunoglobulin-associated and hereditary amyloidosis. In
A amyloidosis, the amyloid protein is AA protein, origi-
ating from serum amyloid-associated (SAA) protein, one
f the main proteins involved in inﬂammatory reaction.
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onsequently, almost any disease associated with chronic
nﬂammation of whatever etiology is liable to amyloidosis
omplications [1].
Amyloid inﬁltration of the thyroid gland is common, but
n aspect of secondary goiter with amyloid deposits is rare.
linically, it is seldom considered, even in case of known
myloidosis [2,3]. Amyloid goiter has been exceptionally
eported as the ﬁrst manifestation of systemic amyloidosis
4].bservation
patient known to have Crohn’s disease presented with goi-
er without signs of compression and with normal thyroid
.
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mFigure 1 Thyroid amyloidosis: interstitial tissue expanded by
abundant amyloid deposit of mature adipose clusters between
thyroid follicles (HE× 400).
function. Cervical ultrasound found a right thyroid nodule.
Lobo-isthmectomy was performed and the specimen was
submitted to analysis.
Examination found a 10× 6-cm2 thyroid lobe connected
to a 2× 1-cm2 isthmus. Sectioning disclosed a homogeneous
brownish aspect without discernable nodule. A diagnosis of
thyroiditis was initially considered, but was ruled out by the
ﬁnal result, which pointed rather to thyroid amyloidosis. The
interstitial tissue was expanded by an acellular eosinophil
deposit, interpreted as ﬁbrosis on histology. A few mature
adipocyte clusters were to be observed between the thyroid
vessels (Fig. 1).
The deposit was marked brick-red on Congo red stain-
ing (Fig. 2), showing yellow-green double refraction under
polarized light.Immunohistochemistry classiﬁed the deposit as AA
(Fig. 3).
This ﬁnding led to exploration for systemic amyloidosis,
subsequently diagnosed on several biopsies.
Figure 2 Congo red staining marks the deposit (Congo
Red× 400).
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wigure 3 Immunohistochemical study on parafﬁn section: the
myloid deposit is of type AA (anti-AA antibody× 400).
iscussion
A amyloid protein, found in amyloid deposits, derives
rom the serum precursor, serum amyloid-associated
rotein (SAA). SAA protein is an apolipoprotein, involved
n inﬂammation, during which its serum concentration
ncreases 100 to 1000-fold under the inﬂuence basically
f interleukin (IL)-6, IL-1 and tumor necrosis factor (TNF).
hronic serum SAA elevation is the basic determining factor
n the onset of amyloidosis in chronic inﬂammatory disease
5]. This said, not all patients with chronic inﬂammatory
isease and prolonged serum SAA elevation go on to develop
myloidosis. There must therefore be further genetic and
nvironmental factors at work [1].
In developing countries, the etiology of secondary inﬂam-
atory amyloidosis is mainly infectious, whereas in Western
ountries chronic inﬂammatory rheumatism and other
hronic inﬂammatory pathologies such as Crohn’s disease,
emorrhagic rectocolitis or Whipple’s disease are more
ften implicated [2]. Among tumors, renal cancer, hepa-
ocellular carcinoma and lymphoma are most frequently
mplicated in AA amyloidosis. Castleman’s disease is one of
he most recently recognized causes and should be investi-
ated in case of apparently idiopathic AA amyloidosis [1].
As chronic infectious disease becomes rarer and many
hronic inﬂammatory diseases are better controlled, at least
n the developed world, the epidemiology of this complica-
ion of inﬂammation is changing; while AA amyloidosis is
ecoming less frequent, its prognosis when it has taken hold
emains poor.
Classically, amyloidosis tends to involve the heart, kid-
eys, lungs, gastro-intestinal tract or peripheral nervous
ystem, but can also affect any other organ. Secondary sys-
emic AA amyloidosis involves the thyroid in 80% of cases
6]. Inﬁltration by microscopic amyloid deposits is often
iscovered serendipitously, in thyroidectomy specimens or
n autopsy. The deposits are asymptomatic, causing nei-
her goiter nor dysthyroidism [2,7]; the quantity of amyloid
eposits is rarely such as to impact thyroid volume. Only
ome 250 cases of amyloid goiter have indeed been reported
orldwide [8].
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Amyloid goiter may be diagnosed by cytopuncture [3,4],
lthough there is a problem of differential diagnosis with
edullary carcinoma, where amyloid deposit is also found in
0% to 80% of cases. Cytopuncture does, however, exclude
ther thyroid cancers, notably anaplastic cancer and lym-
homa [6]. Anatomopathology enables positive diagnosis in
ase of amyloid deposit detected in the form of an amor-
hous substance showing yellow-green double refraction
nder polarized light on Congo red staining. As in the present
bservation, an aspect of adipose tissue interposed between
he thyroid vessels is highly characteristic.
Amyloidosis typing is based on immunohistochemistry, as
n the present case.
Eradicating infectious diseases such as tuberculosis or
eprosy is of preventive value with regard to AA amyloidosis.
t is certainly too soon to speak of the eradication of chronic
nﬂammatory disease, but more powerful anti-inﬂammatory
gents have reduced the incidence of associated amyloido-
is over recent years. Regular monitoring of serum SAA could
elp in controlling inﬂammation and preventing amyloidosis
9].
Once amyloidosis has taken hold, etiological manage-
ent of the underlying pathology remains mandatory.
Reducing the availability of amyloid protein precursor
o as to halt deposit progression is at present the most
ogical treatment strategy in all forms of amyloidosis. In
he case of AA amyloidosis, evolution seems directly bound
o the control of inﬂammation and of serum SAA levels
10].
onclusionA amyloidosis is a serious complication of chronic inﬂam-
ation. Incidence is falling as certain chronic infections
ecome rarer and earlier and more powerful treatment of
hronic inﬂammatory disease spreads. An aspect of amyloid
oiter as the ﬁrst manifestation of systemic amyloidosis is
[E. Kazdaghli Lagha et al.
xceptional, and rarely considered even in case of known
myloidosis.
Positive diagnosis of AA amyloidosis requires combined
linical and histologic data, and immunohistochemistry in
articular, for differentiation with respect to other vari-
ties. Once the disease established, prognosis remains poor.
Progress in treatment is needed, and notably the devel-
pment of drugs targeting the early stages of amylogenesis.
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